These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 1134911)

  • 1. [The responsibility of the pharmaceutical industry].
    Andersen K
    Nord Med; 1975 Apr; 90(4):115. PubMed ID: 1134911
    [No Abstract]   [Full Text] [Related]  

  • 2. [Responsibility of the pharmaceutical industry toward the first undesirable effects of new products].
    Juillet Y; de Cremiers F
    Therapie; 1988; 43(5):385-8. PubMed ID: 3227498
    [No Abstract]   [Full Text] [Related]  

  • 3. [The "third party" in the pharmaceutical industry].
    Karrer E
    Boll Chim Farm; 1966 Aug; 105(8):563-9. PubMed ID: 6003361
    [No Abstract]   [Full Text] [Related]  

  • 4. Opinions of pharmacy, medicine, and pharmaceutical industry leaders about hypothetical therapeutic-interchange legislation.
    Segal R; Grines LL; Pathak DS
    Am J Hosp Pharm; 1988 Mar; 45(3):570-7. PubMed ID: 3369459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Considerations for developing an antiarrhythmic agent: a perspective from the pharmaceutical industry.
    Antonaccio MJ
    Can J Cardiol; 1994 Apr; 10(3):325-6. PubMed ID: 8162528
    [No Abstract]   [Full Text] [Related]  

  • 6. [Some aspects of pharmaceutical control in Europe].
    Scowen EF
    Cah Med; 1973 Apr; 14(4):307-9. PubMed ID: 4742880
    [No Abstract]   [Full Text] [Related]  

  • 7. [Pharmaceutical brandnames].
    Jacobs P
    Ned Tijdschr Geneeskd; 1975 May; 119(20):785-9. PubMed ID: 1161070
    [No Abstract]   [Full Text] [Related]  

  • 8. The "Long" amendment.
    Provost GP
    Am J Hosp Pharm; 1967 Dec; 24(12):665. PubMed ID: 6073365
    [No Abstract]   [Full Text] [Related]  

  • 9. The pharmaceutical industry -- will Canada become a major research centre?
    Gray C
    Can Med Assoc J; 1981 Apr; 124(7):910, 914-5, 918 concl. PubMed ID: 7214290
    [No Abstract]   [Full Text] [Related]  

  • 10. [Swiss pharmaceutical legislation].
    GIRARDET ME
    Prod Pharm; 1960 Mar; 15():130-1. PubMed ID: 13828130
    [No Abstract]   [Full Text] [Related]  

  • 11. The brand name versus generic controversy: Is there a segment of the pharmaceutical industry that produces drugs of higher quality?
    Marsh DA; Hoar ME
    Contemp Pharm Pract; 1982; 5(2):130-5. PubMed ID: 10317245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Standing on your own feet.
    Apple WS
    J Am Pharm Assoc; 1974 Jun; 14(6):278-80. PubMed ID: 4840422
    [No Abstract]   [Full Text] [Related]  

  • 13. No room for compromise. Bill C-22.
    McGillivray D
    CPJ; 1988 Feb; 121(2):88-9. PubMed ID: 10285967
    [No Abstract]   [Full Text] [Related]  

  • 14. [Pharmacy in Norway].
    Karlsen J
    Pharm Weekbl; 1967 Aug; 102(31):771-4. PubMed ID: 5591081
    [No Abstract]   [Full Text] [Related]  

  • 15. The economic wisdom of regulating pharmaceutical "freebies".
    Fisher SH
    Duke Law J; 1991 Feb; (1):206-39. PubMed ID: 10114416
    [No Abstract]   [Full Text] [Related]  

  • 16. Drug sampling: legislation proposed; industry receptive to ending practice.
    Gatty B
    Hosp Formul; 1994 Jun; 29(6):478, 477. PubMed ID: 10134577
    [No Abstract]   [Full Text] [Related]  

  • 17. Recent developments in pharmaceutical products liability law: failure to warn, the learned intermediary defense, and other issues in the new millennium.
    Garbutt BJ; Hofmann ME
    Food Drug Law J; 2003; 58(2):269-86. PubMed ID: 12866558
    [No Abstract]   [Full Text] [Related]  

  • 18. [Quality control in pharmaceutic industry].
    de Oliveira E
    Hospital (Rio J); 1969 Feb; 75(2):543-61. PubMed ID: 5311212
    [No Abstract]   [Full Text] [Related]  

  • 19. The role of government as it affects the pharmaceutical industry and profession.
    HOLLAND AH
    Am J Pharm Sci Support Public Health; 1955 May; 127(5):158-63. PubMed ID: 13354727
    [No Abstract]   [Full Text] [Related]  

  • 20. Brands or generics: the dilemma of pharmaceutical marketing in a developing country.
    Quraeshi ZA; Luqmani M; Malhotra N
    J Health Care Mark; 1983; 3(4):27-37. PubMed ID: 10264767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.